VLP Vaccine Developed Against Coronavirus Prepares For Phase Phase

vlp vaccine phase is preparing vlp vaccine developed against coronavirus is preparing for phase phase
vlp vaccine phase is preparing vlp vaccine developed against coronavirus is preparing for phase phase

Industry and Technology Minister Mustafa Varank visited the facility where toxicity tests of one of the innovative vaccine studies based on virus-like particles (VLP) developed against the new type of coronavirus (Kovid-19) were conducted. Vaccine Phase-1 to shift the work Varank stating that the emergence of the intermediate results of these tests, "God willing, our planned manner at the beginning of this month or at the end of February with be positive test results, Turkey Pharmaceuticals and Medical Devices Agency (TİTCK) vaccine study in Turkey with the approval It will be in phase phase. " said.

Ministers Varank, TUBITAK-19 Covidien has reviewed some projects over vaccines and drugs work in laboratory toxicity tests in Turkey where the platform. Varank, who visited Kobay Experimental Animals Laboratory Inc. in METU Teknokent OSTİM Center, received information about the studies carried out from the founder of the company, Veterinarian Begüm Buğdaycı Açıkkol.

Varank, where after examination of his evaluation, guinea pigs AŞ, Turkey's first private sector GLP (good laboratory practice) said it was certified laboratory.

all over the world Kovid-19's emerging as a problem, scientific studies pointing to fight the virus as they do Varank country, all the ability in Turkey in this context stressed that they mobilized.

Drawing attention to the fact that toxicity tests constitute an important part of the ongoing drug and vaccine studies, Varank said, “You need facilities with some standards to do these. We have a similar infrastructure in Izmir Biomedicine and Genome Center, based on the Law on the Support of Research Infrastructures. Ministry of Health also has a facility capable of toxicity tests with GLP certificate that way, but we saw that we actually also have a private sector investment made in this area in Turkey. " he spoke.

Referring to the work carried out in the laboratory, Varank gave the following information:

“We conduct the toxicity studies of one of the most innovative vaccine studies in the world based on virus-like particles in this facility that has received the GLP certificate. In order to proceed to the Phase-1 phase of this vaccine, intermediate results of these tests must be concluded. Hopefully we plan the end of this month or in early February with the test results are positive, with the consent titck'n a vaccine studies in Turkey will be passed on to the more technical stages. Our Ministry of Health follows the issue very closely. "

"WE HAVE GREAT CAPABILITIES IN THE SCIENTIFIC FIELD"

Varank, stated that arise with the idea of ​​a young entrepreneur's property, "the private sector to be invested in such a strategic area in Turkey and the world from the arrival of the offer to work with this company he was attracted my curiosity. I saw these facilities and congratulated them on getting GLP certificates. " found the assessment.

Turkey is a major scientific capabilities in the area, he stressed that seen in studies of vaccines and drugs Varank, said:

"We raised up together with capacity in Turkey in the coming period we will see our country as a powerful country in the health field. I am pleased that such a facility is found in Ankara and implemented by a young entrepreneur. Tests are also carried out here on other vaccine studies. We will continue to serve all of Turkey and increasing the number of such facilities. "

"We PERFORM TURKEY'S FIRST TEST ANIMAL EXPORTS the"

Begum Buğdaycı Açıkkol the "Production and Research Laboratory of Experimental Animals in Turkey Project Start" and "There Is it an idea?" He said he was first in the competition.

Açıkkol stated that the private sector established the first experimental animal production laboratory in 2008, and a year later, they established a research laboratory within the scope of the Local Ethics Committee, where R&D studies can be carried out with the support of TÜBİTAK.

Açıkkol, pointing out that they offer services related to the import of animal experiments can not be reached by researchers, "Turkey's exports have performed the first experiments on animals in Uruguay. We ensured that mice made in Turkey are exported to a pharmaceutical company in Hungary with their licenses and used in studies. " said.

Açıkkol emphasized that they later focused on good laboratory practices and said:

“We have developed our infrastructure on this issue since 2017. When the vaccination studies started, we made our application to the Turkish Accreditation Agency (TÜRKAK). We received our certificate after the audits we had regarding our works evaluated within the scope of GLP. We started to serve in this field with chronic toxicity, repeat dose toxicity, in-vitro and in-vivo GLP studies. "

"WE AIM TO ELIMINATE THE ABROAD ADDICTION ON HUMANIZED MICE"

Açıkkol stated that the experiments of 19 vaccines against Kovid-4 and a drug study are continuing in their own laboratories, and used the following statements:

“Within the scope of our newly approved TÜBİTAK project, Prof. Dr. We will produce "humanized" mice with Güneş Esendağlı. And we will produce humanized mice that can offer services to researchers and researchers can make the vaccine they developed after working on these mice when they try to answer as human future produced in Turkey. In this regard, we aim to completely eliminate foreign dependency. We will put these mice imported at high costs into the service of researchers at low costs. "

Stating that they also produced "nude" mice used in cancer studies, Açıkkol said, “Before we had a large production capacity, nude mice were imported from abroad. Within the scope of our TÜBİTAK project, we were able to create an infrastructure for the production, maintenance and R&D studies of nude mice. For nearly 10 years, we have made nude mice available for research studies conducted at Kobay AŞ and for researchers at other universities. " said.

Armin

sohbet

    Be the first to comment

    Comments